A new phenotypic classification of bone marrow plasmacytosis.
Here, we propose a new phenotypic classification of bone marrow plasmacytosis. By 2-color phenotypic analysis with FITC anti-CD38 and PE anti-CD19, -CD56, -VLA-5 or MPC-1 antibody, plasma cells are easily identified on the histogram, even though no more than 1% of plasma cells are found in the bone marrow. Hence, plasma cells are phenotypically classified into polyclonal (reactive) (CD19+CD56-) or monoclonal (neoplastic) plasma cells (mostly CD19-CD56+), and furthermore immature (VLA-5-MPC-1-), intermediate (VLA-5-MPC-1+) and mature plasma cells (VLA-5+MPC-1+). According to these findings, plasmacytosis in the bone marrow can be classified into polyclonal marrow plasmacytosis (POMP) and monoclonal marrow plasmacytosis (MOMP) states. The MOMP state is further subclassified into MOMP-1 and MOMP-2, MOMP-3 and MOMP-4; MOMP-1 is defined by co-existence of monoclonal plasma cells and polyclonal plasma cells, and MOMP-2 to MOMP-4 are dependent on increased proportions of VLA-5-MPC-1- immature myeloma (plasma) cells. We found that the cases of benign monoclonal gammopathy (BMG) according to the conventional classification were in the MOMP-1 state, and myelomas could be classified into the MOMP-2 to MOMP-4 state. Subclassification of the MOMP state may be useful in determining the prognosis of myelomas, where an increase in immature myeloma cells is reported to correlate well with their aggravation during the clinical courses. Therefore, this new phenotypic classification of bone marrow plasmacytosis (POMP and MOMP-1 to MOMP-4) will contribute to differential diagnosis and understanding of therapeutic responses and prognosis in myelomas.
Kawano
M M
MM
Department of Hematology and Oncology, Hiroshima University, Japan.
Mihara
K
K
Tsujimoto
T
T
Huang
N
N
Kuramoto
A
A
D018941:Antigens, CD19 / Q000032:analysis; D000943:Antigens, Differentiation / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology*; D019002:CD56 Antigen / Q000032:analysis; D005434:Flow Cytometry; D006942:Hypergammaglobulinemia / Q000473:pathology; D039041:Integrin alpha4beta1; D016023:Integrins / Q000032:analysis; D009101:Multiple Myeloma / Q000473:pathology; D010265:Paraproteinemias / Q000473:pathology*; D010641:Phenotype; D010950:Plasma Cells / Q000737:chemistry / Q000473:pathology*; D017469:Receptors, Fibronectin / Q000032:analysis; D016201:Receptors, Lymphocyte Homing / Q000032:analysis
D018941:Antigens, CD19; D000943:Antigens, Differentiation; D019002:CD56 Antigen; D039041:Integrin alpha4beta1; D016023:Integrins; D017469:Receptors, Fibronectin; D016201:Receptors, Lymphocyte Homing